Synnocare

Nanjing Synnocare Pharmaceutical Technology Co., Ltd. focuses on unmet clinical needs and difficult drug targets, paying attention to areas such as malignant tumors, autoimmune diseases, and central nervous system disorders. By integrating AI and multi-omics technologies, the company applies these technologies throughout all stages of new drug development, including target discovery, molecular design, and clinical trial design, with the aim of developing original small-molecule drugs with global intellectual property rights.